Clinical Trials on Advanced Primary Peritoneal Carcinoma

Total 8186 results

Peking University Cancer Hospital & Institute

Recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (BRAND)

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

China
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
University of Oklahoma
Genentech, Inc.

Completed

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Advanced Ovarian Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
Emory University
Astex Pharmaceuticals, Inc.

Recruiting

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Head and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...

United States
Polaris Group

Terminated

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP)

Glioma | Hepatocellular Carcinoma | Uveal Melanoma | Sarcomatoid Carcinoma | Pleural Mesothelioma Malignant Advanced | Peritoneal Mesothelioma Malignant Advanced | Non-squamous Non-small Cell Lung Carcinoma

United States, United Kingdom
John P. Fruehauf
GlaxoSmithKline

Completed

Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer

Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer

Quality of Life | Ovarian Cancer | Malignant Tumor of Peritoneum

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions
Roswell Park Cancer Institute
National Cancer Institute (NCI); Sanofi Pasteur, a Sanofi Company

Completed

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
Ira Winer

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Malignant Ovarian Epithelial Tumor | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Oslo University Hospital
The Research Council of Norway

Recruiting

Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies (PSM)

Mesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian Carcinoma

Norway
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
Ronald Buckanovich
Genentech, Inc.

Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog Inhibitor

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
M.D. Anderson Cancer Center

Active, not recruiting

Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...

United States
Association Francaise de Chirurgie

Completed

Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin

Carcinomatosis, Peritoneal

France
Postgraduate Institute of Medical Education and...

Terminated

Comparison of "Roll-over' Technique With Standard Abdominal Paracentesis in Suspected Peritoneal Carcinomatosis (ROLLON)

Ascites | Peritoneal Carcinomatosis | Peritoneum Neoplasm | Tuberculous Peritonitis

India
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Charite University, Berlin, Germany
German Cancer Aid

Completed

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC)

Malignant Neoplasm of Stomach | Secondary Malignant Neoplasm of Peritoneum | Secondary Malignant Neoplasm of Other and Unspecified Sites

Germany
Hasselt University
Ziekenhuis Oost-Limburg

Unknown

Concentration- Versus Body Surface Area-based HIPEC in Colorectal Peritoneal Carcinomatosis' Treatment (COBOX)

Colorectal Peritoneal Carcinomatosis

Belgium
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies

Peritoneal Neoplasms | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Cervical Carcinoma | Ovarian Carcinoma | Recurrent Cervical Carcinoma | Uterine Corpus Cancer | Vulvar Carcinoma | Primary Peritoneal Carcinoma | Recurrent Vulvar Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma

United States
Case Comprehensive Cancer Center

Completed

Debulking Surgery in Ovarian Cancer (MIID-SOC)

Malignant Neoplasm of Ovary | Malignant Neoplasm of Fallopian Tube | Malignant Neoplasm of Peritoneum

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
ARCAGY/ GINECO GROUP

Completed

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

France
Oncoinvent AS

Active, not recruiting

Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

Peritoneal Carcinoma | Colorectal Carcinoma

Norway, Sweden
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Eli Lilly and Company

Completed

Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cancer

Germany, Argentina, Canada, Poland, Sweden
Floyd & Delores Jones Cancer Institute at Virginia...

Completed

Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University of Washington
GlaxoSmithKline

Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic... and other conditions

United States
M.D. Anderson Cancer Center

Completed

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Peritoneal Cancer

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC; ImmunoVaccine Technologies, Inc. (IMV Inc.)

Active, not recruiting

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Advanced Cancer | Primary Peritoneal Carcinoma

Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab (IIPOP)

Patients With Gastric Peritoneal Carcinomatosis

France
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

United States

Clinical Trials on Advanced Primary Peritoneal Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations